Savara Inc (SVRA)
1.68
-0.03 (-1.75%)
USD |
NASDAQ |
Aug 15, 16:00
1.69
+0.01 (+0.60%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 191.59M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 41.18% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 1.508 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 98.44% |
News
Headline
Wire
Time (ET)
Yahoo
07/11 08:05
MT Newswires
06/16 10:27
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
11/11/2022* | -- | Results | Q3 2022 | -- | -0.07 | -- | |
08/11/2022 | -- | Results | Q2 2022 | -0.06 | -0.06 | 0.00% | |
05/11/2022 | -- | Results | Q1 2022 | -0.05 | -0.08 | 37.50% | |
03/30/2022 | -- | Results | Q4 2021 | -0.07 | -0.07 | -3.70% | |
11/12/2021 | -- | Results | Q3 2021 | -0.07 | -0.09 | 25.53% | |
08/12/2021 | -- | Results | Q2 2021 | -0.07 | -0.12 | 41.67% | |
05/13/2021 | -- | Results | Q1 2021 | -0.13 | -0.10 | -36.84% | |
11/05/2020 | -- | Results | Q3 2020 | -0.18 | -0.21 | 12.20% |
*Estimated Date/Time
Earnings
Profile
Edit
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). |
URL | https://www.savarapharma.com |
Investor Relations URL | https://savarapharma.com/investors/events-presentations/ |
HQ State/Province | Texas |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Nov. 11, 2022 (est.) |
Last Earnings Release | Aug. 11, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | -- |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.00 |
Yield to Sector | 0.00 |
Yield to Industry | 0.00 |
Last Dividend Amt. | -- |
Dividend Frequency | -- |
Last Ex-Dividend Date | -- |
Yield (TTM) | 0.00% |
Forward Yield | -- |
Payout Ratio | -- |
Cash Payout Ratio | -- |
Consistent Payer (5Y) | No |
Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of August 15, 2022.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
Revenue (TTM) | -- |
Total Expenses (TTM) | 37.61M |
Net Income (TTM) | -39.32M |
Total Assets (Quarterly) | 156.78M |
Total Liabilities (Quarterly) | 29.74M |
Shareholders Equity (Quarterly) | 127.04M |
Cash from Operations (TTM) | -36.03M |
Cash from Investing (TTM) | 90.58M |
Cash from Financing (TTM) | 0.103M |
Ratings
Profile
Edit
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). |
URL | https://www.savarapharma.com |
Investor Relations URL | https://savarapharma.com/investors/events-presentations/ |
HQ State/Province | Texas |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Nov. 11, 2022 (est.) |
Last Earnings Release | Aug. 11, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Risk Info
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Morningstar | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
SVRA Tweets |